Taha A S, Dahill S, Nakshabendi I, Lee F D, Sturrock R D, Russell R I
Department of Gastroenterology, Royal Infirmary, Glasgow.
Gut. 1993 Sep;34(9):1162-6. doi: 10.1136/gut.34.9.1162.
Duodenitis and gastric metaplasia, which is often colonised by Helicobacter pylori (H pylori), are increasingly recognised for their importance in the pathogenesis of duodenal ulcers. The situation is not clear in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs), who have a higher risk of peptic ulceration. The aim of this study was to identify the duodenal histological abnormalities in the presence or absence of NSAIDs, H pylori, and duodenal ulceration. Endoscopic duodenal biopsy specimens were taken from healthy looking mucosa of 172 patients (74 took NSAIDs, and 98 did not). Duodenitis was graded according to the degree of neutrophilic and plasma cell infiltration, villus height, Brunner's gland prolapse, and gastric metaplasia. The activity of duodenitis was dependent on the neutrophilic infiltration. A global score covering all the above factors was constructed, and H pylori in both the stomach and duodenum, was also assessed. The results showed that duodenitis with varying degrees of neutrophilic infiltration and gastric metaplasia was found in 20 patients (27%) taking NSAIDs, compared with 56 patients (57%) not taking NSAIDs (chi 2 = 16.24, p < 0.001). This degree of duodenitis was also found in 20 of 25 patients (80%) with duodenal ulcers, regardless of NSAID intake (chi 2 = 15.38, p < 0.001). Gastric metaplasia was identified in 20 patients (27%) receiving NSAIDs and 38 (39%) not receiving NSAIDs. Duodenal H pylori was only seen in patients with gastric metaplasia 10 (50%) receiving NSAIDs, and 34 (89%) not receiving NSAIDs. H pylori positive gastritis, and the combination of active duodenitis and gastric metaplasia were independent predictors of duodenal ulceration. It is concluded that active duodenitis is less common in patients taking NSAIDs but is strongly associated with gastric metaplasia, H pylori positive gastritis, and duodenal ulceration. These findings are relevant to the pathogenesis and treatment of duodenal ulcers in patients taking NSAIDs.
十二指肠炎症和胃化生(常被幽门螺杆菌定植)在十二指肠溃疡发病机制中的重要性日益受到认可。在服用非甾体抗炎药(NSAIDs)的患者中情况尚不清楚,这类患者发生消化性溃疡的风险更高。本研究的目的是确定在有或无NSAIDs、幽门螺杆菌及十二指肠溃疡的情况下十二指肠的组织学异常。从172例患者外观正常的黏膜获取内镜下十二指肠活检标本(74例服用NSAIDs,98例未服用)。根据中性粒细胞和浆细胞浸润程度、绒毛高度、Brunner腺脱垂及胃化生对十二指肠炎症进行分级。十二指肠炎症的活性取决于中性粒细胞浸润。构建涵盖上述所有因素的综合评分,并评估胃和十二指肠中的幽门螺杆菌。结果显示,服用NSAIDs的20例患者(27%)存在不同程度中性粒细胞浸润和胃化生的十二指肠炎症,未服用NSAIDs的56例患者(57%)中也有此情况(χ² = 16.24,p < 0.001)。无论是否服用NSAIDs,25例十二指肠溃疡患者中有20例(80%)也有这种程度的十二指肠炎症(χ² = 15.38,p < 0.001)。服用NSAIDs的20例患者(27%)和未服用NSAIDs的38例患者(39%)发现有胃化生。仅在有胃化生的患者中发现十二指肠幽门螺杆菌,服用NSAIDs的患者中有10例(50%),未服用NSAIDs的患者中有34例(89%)。幽门螺杆菌阳性胃炎以及活动性十二指肠炎症和胃化生的组合是十二指肠溃疡的独立预测因素。得出结论,服用NSAIDs的患者中活动性十二指肠炎症较少见,但与胃化生、幽门螺杆菌阳性胃炎及十二指肠溃疡密切相关。这些发现与服用NSAIDs患者十二指肠溃疡的发病机制和治疗相关。